<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090113</url>
  </required_header>
  <id_info>
    <org_study_id>2014ZX09201022-010-11</org_study_id>
    <nct_id>NCT03090113</nct_id>
  </id_info>
  <brief_title>Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism</brief_title>
  <acronym>SPACE</acronym>
  <official_title>A Random, Double-blind, Parallel, Placebo-controlled, Multi-center Study of Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tiantan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tiantan Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, placebo-controlled, parallel, multicenter research in
      order to evaluate the effect of Shuxuetong injection in prevention of symptomatic or
      asymptomatic new cerebral infarction within 10 days.

      Subgroup study：Evaluate the role of advanced diagnostic technique in identifying potential
      causes of Embolic Stroke of Undetermined Source (ESUS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Shuxuetong injection or Placebo injection for 10days. About 2416 patients randomized at 80
      centers all over China with 20 subgroup study centers.

      Face to face interview at baseline, 10 days, and 90 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 12, 2017</start_date>
  <completion_date type="Actual">June 21, 2019</completion_date>
  <primary_completion_date type="Actual">March 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic or Asymptomatic New Cerebral Infarction</measure>
    <time_frame>10 days</time_frame>
    <description>Those patients who are still alive at 10 days after randomization will be contacted to set up a follow-up clinical visit. Information of recurrent symptomatic cerebral infarction will be collected and MRI examination will be performed to detect asymptomatic new cerebral infarction.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Cerebral Infarction</measure>
    <time_frame>10 days</time_frame>
    <description>Those patients who are still alive at 10 days after randomization will be contacted to set up a follow-up clinical visit. Information of recurrent symptomatic cerebral infarction will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Asymptomatic Cerebral Infarction</measure>
    <time_frame>10 days</time_frame>
    <description>Those patients who are still alive at 10 days after randomization will be contacted to set up a follow-up clinical visit. MRI examination including diffusion weighted imaging (DWI) sequence will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral Infarction Volume Expansion</measure>
    <time_frame>10 days</time_frame>
    <description>Those patients who are still alive at hospital discharge will be contacted to set up a follow-up clinical visit. MRI examination will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS Score Increase</measure>
    <time_frame>10 days</time_frame>
    <description>Those patients who are still alive at hospital discharge will be contacted to set up a follow-up clinical visit. Neurological and functional assessments including NIHSS will be performed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Symptomatic Stroke(Cerebral infarction, cerebral hemorrhage)</measure>
    <time_frame>90 days</time_frame>
    <description>Those patients who are still alive at 90days after onset will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent symptomatic stroke will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Symptomatic Ischemic Stroke</measure>
    <time_frame>90 days</time_frame>
    <description>Those patients who are still alive at 90days after onset will be contacted by telephone to set up a follow-up clinical visit. Information of recurrent symptomatic ischmemic stroke will be collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined Vascular Events</measure>
    <time_frame>90 days</time_frame>
    <description>Combined Vascular Events was defined as a combination of symptomatic stroke, myocardial infarction and vascular death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability or Death</measure>
    <time_frame>90 days</time_frame>
    <description>Disability or Death was defined as a score of 3 to 6 on the modified Rankin Scale at 90days after onset.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Detected an Atrial Fibrillation Persistent ≥ 30s</measure>
    <time_frame>90 days</time_frame>
    <description>Pre-specified Outcomes for Substudy of 'Etiology Study in Patients with ESUS'</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2416</enrollment>
  <condition>Embolic Stroke</condition>
  <arm_group>
    <arm_group_label>Shuxuetong Injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Shuxuetong Injection,12ml,ivgtt,day1; Shuxuetong Injection,6ml,ivgtt,day2 to day10;</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Injection,12ml,ivgtt,day1; Placebo Injection,6ml,ivgtt,day2 to day10;</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Shuxuetong Injection</intervention_name>
    <description>intravenous drip</description>
    <arm_group_label>Shuxuetong Injection</arm_group_label>
    <other_name>Shuxuetong</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Injection</intervention_name>
    <description>intravenous drip</description>
    <arm_group_label>Placebo Injection</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. More than or equal to 18 years old and less than 80 years old;

          2. Acute ischemic stroke, brain magnetic resonance imaging showed non lacunar infarction
             (subcortical infarction less than or equal to 1.5 cm);

          3. Onset within 72 hours;

          4. Patients or their family members are willing to sign the informed consent.

        Exclusion criteria

          1. Intracranial hemorrhage: cerebral hemorrhage, subarachnoid hemorrhage, etc.;

          2. Transient ischemic attack;

          3. Lacunar infarction;

          4. History of acute stroke within 6 months;

          5. Clear diagnosis of other causes of ischemic stroke (arterial dissection, arteritis,
             vasospasm, etc.);

          6. The acute infarcts lesion more than one-half lobe in size;

          7. Preceding modified Rankin Scale (mRS) score ≥ 2;

          8. Cumulative usage of traditional Chinese medicine which activating blood circulation
             more than 3 times after onset, including but not limited to: Danhong, Xueshuantong,
             Xuesaitong, Ginkgo biloba, sodium ozagrel, Salvia miltiorrhiza, ligustrazine, Erigeron
             breviscapus, etc;

          9. Chronic liver disease, liver and kidney dysfunction, lifted alanine aminotransferase
             (＞3 times the ULN), lifted serum creatinine (＞2 times the ULN）;

         10. History of coagulopathy, systemic bleeding, thrombocytopenia or neutropenia;

         11. Blood pressure ＞90/60 mmHg or ≤220/120 mmHg after treatment;

         12. Serious heart or lung disease, in the judgment of clinical study staff, would not
             suitable to participant in the trial;

         13. Patients with atrial fibrillation who were scheduled or likely to receive
             anticoagulant therapy with unfractionated heparin or low molecular weight heparin
             within 2 weeks after randomization

         14. A medical condition likely to limit survival to less than three months or any other
             condition judged by the clinic team to likely limit the adherence to study procedures;

         15. Known allergies for ingredients of the drug, allergy history for food or drug;

         16. Pregnant, currently trying to become pregnant, or of child-bearing potential and not
             using birth control;

         17. Participation in another clinical trial within 30 days;

         18. Unable to understand and/or comply with the study procedures and/or follow-up studies
             due to mental illness, cognitive or emotional disorders.

        Subgroup Exclusion Criteria

          1. History of atrial fibrillation

          2. Atrial fibrillation in 12-lead electrocardiogram (ECG);

          3. Heart rate monitoring (dynamic electrocardiogram telemetry) up to 20 hours or more
             detected atrial fibrillation for 6 minutes or more;

          4. Intracardiac thrombosis in thoracic or esophageal echocardiography;

          5. Occlusion or proximal vessel infarction for more than 50%.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang yongjun, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tian Tan Hospital, Capital Medical University, Beijing, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wuhu No.1 People's Hospital</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Tian Tan Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ansteel Group Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beiujing Fengtai Youanmen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Fangshan District</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yongchuan hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Chongqing</city>
        <state>Chongqing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Houjie Hospital</name>
      <address>
        <city>Dongguan</city>
        <state>Guangzhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cangzhou Peoole's Hospital</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Hejian</name>
      <address>
        <city>Cangzhou</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuancheng County Hospital</name>
      <address>
        <city>Chengde</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Traditional Chinese Medicine Hospital of Qiu County</name>
      <address>
        <city>Handan</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hengshui Fourth Hospital</name>
      <address>
        <city>Hengshui</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jizhou District Hospital of Hengshui</name>
      <address>
        <city>Hengshui</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shijiazhuang Pingan Hospital Affiliated to Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Jiamusi University</name>
      <address>
        <city>Jiamusi</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heilongjiang Province Agricultural Reclamation Mudanjiang Authority Central Hospital</name>
      <address>
        <city>Mudanjiang</city>
        <state>Heilongjiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Handan Municipal Center Hospital</name>
      <address>
        <city>Handan</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of University of South China</name>
      <address>
        <city>Hengyang</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Zhongmu</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhengzhou Yihe Hospital Affiliated to Henan University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jingmen City Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Jingmen</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wuhan NO.1 Hospital,Wuhan Hospital Of Traditional Chinese And Western Medicine</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital of TCM</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantong 3rd People's Hospital</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhangjiagang First People's Hospital</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zhangjiagang Hospital of Traditional Chinese Medicine affiliated to Nanjing University of Chinese Medicine</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Xuzhou Medical College</name>
      <address>
        <city>Xuzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangxi Provincial People's Hospital</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University-the Eastern Division</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Huludao</name>
      <address>
        <city>Huludao</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jinzhou Medical University</name>
      <address>
        <city>Jinzhou</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Baotou Medical College</name>
      <address>
        <city>Baotou</city>
        <state>Neimenggu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wu Yuan People's Hospital</name>
      <address>
        <city>Bayan Nur</city>
        <state>Neimenggu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Chifeng University</name>
      <address>
        <city>Chifeng</city>
        <state>Neimenggu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huimin People's Hospital</name>
      <address>
        <city>Binzhou</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ningjin County People's Hospital</name>
      <address>
        <city>Dezhou</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Western Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Penglai</name>
      <address>
        <city>Penglai</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Qingdao West Coast New Area</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Qingdao Haci medical group hospital</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Qingdao University</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Hospital of Shanxi Medical University</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second People's Hospital of Shenzhen</name>
      <address>
        <city>Shenzhen</city>
        <state>Shenzhen</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dongyang People's Hopital</name>
      <address>
        <city>Dongyang</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lishui People's Hospital</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>No.1 People's Hospital of Taizhou</name>
      <address>
        <city>Taizhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruian People's Hospital</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>March 9, 2017</study_first_submitted>
  <study_first_submitted_qc>March 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>July 21, 2020</last_update_submitted>
  <last_update_submitted_qc>July 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tiantan Hospital</investigator_affiliation>
    <investigator_full_name>Yongjun Wang</investigator_full_name>
    <investigator_title>Executive Vice-President</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Embolic Stroke</keyword>
  <keyword>Shuxuetong</keyword>
  <keyword>Recurrence</keyword>
  <keyword>Symptomatic New Cerebral Infarction</keyword>
  <keyword>Asymptomatic New Cerebral Infarction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

